MX2013005915A - Inhibidores de kat ii. - Google Patents

Inhibidores de kat ii.

Info

Publication number
MX2013005915A
MX2013005915A MX2013005915A MX2013005915A MX2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A MX 2013005915 A MX2013005915 A MX 2013005915A
Authority
MX
Mexico
Prior art keywords
hydroxy
amino
kat
inhibitors
dihydroquinolin
Prior art date
Application number
MX2013005915A
Other languages
English (en)
Inventor
Patrick Robert Verhoest
Amy Beth Dounay
Christopher John Helal
Jamison Bryce Tuttle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013005915A publication Critical patent/MX2013005915A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a compuestos de 3-amino-1-hidroxi-2-oxo-1, 2, 3,4-tetrahidroquinolina-7-carbonitri lo, 3-amino-1-hidroxi-7-(2-metoxietoxi)-3,4-dihidroquinolin-2(1H) -ona y 3-amino-1-hidroxi-7-[(1S)-2-metoxi-1-metiletoxi]-3,4-dihidr oquinolin-2(1H)-ona, incluyendo mezclas racémicas y enantiómeros resueltos de los mismos, a sales farmacéuticamente aceptables de los mismos y al tratamiento de déficits cognitivos asociados con esquizofrenia y otros trastornos psiquiátricos, neurodegenerativos y/o neurológicos en mamíferos, incluyendo seres humanos.
MX2013005915A 2010-12-01 2011-11-18 Inhibidores de kat ii. MX2013005915A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41879110P 2010-12-01 2010-12-01
US41923210P 2010-12-02 2010-12-02
PCT/IB2011/055190 WO2012073146A1 (en) 2010-12-01 2011-11-18 Kat ii inhibitors

Publications (1)

Publication Number Publication Date
MX2013005915A true MX2013005915A (es) 2013-07-03

Family

ID=45315857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005915A MX2013005915A (es) 2010-12-01 2011-11-18 Inhibidores de kat ii.

Country Status (14)

Country Link
US (1) US8487104B2 (es)
EP (1) EP2646417A1 (es)
JP (1) JP5868994B2 (es)
KR (1) KR101522803B1 (es)
CN (1) CN103228631B (es)
AR (1) AR084051A1 (es)
AU (1) AU2011336217B2 (es)
CA (1) CA2819106C (es)
HK (1) HK1187611A1 (es)
IL (1) IL226668A (es)
MX (1) MX2013005915A (es)
SG (1) SG190246A1 (es)
WO (1) WO2012073146A1 (es)
ZA (1) ZA201303412B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186666A1 (en) * 2012-06-15 2013-12-19 Pfizer Inc. Tricyclic compounds as kat ii inhibitors
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
TWI693227B (zh) * 2014-04-23 2020-05-11 日商田邊三菱製藥股份有限公司 新穎二環性或三環性雜環化合物
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
WO2017069275A1 (ja) * 2015-10-22 2017-04-27 田辺三菱製薬株式会社 新規二環性複素環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
JPH0881443A (ja) * 1994-09-12 1996-03-26 Otsuka Pharmaceut Co Ltd 細胞外マトリックス金属プロテアーゼ阻害剤
WO2005007628A1 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
EP2222662A4 (en) * 2007-11-15 2011-08-03 Univ Maryland INHIBITORS OF KYNURENINE AMINO TRANSFERASE
CN102482221B (zh) * 2009-06-18 2014-10-22 美国辉瑞有限公司 作为katii抑制剂的双环和三环化合物
SG190207A1 (en) 2010-12-01 2013-06-28 Pfizer Kat ii inhibitors

Also Published As

Publication number Publication date
CA2819106A1 (en) 2012-06-07
AU2011336217A1 (en) 2013-06-06
AR084051A1 (es) 2013-04-17
JP5868994B2 (ja) 2016-02-24
CA2819106C (en) 2015-12-29
SG190246A1 (en) 2013-06-28
KR101522803B1 (ko) 2015-05-26
CN103228631B (zh) 2015-04-29
WO2012073146A1 (en) 2012-06-07
US20120142729A1 (en) 2012-06-07
ZA201303412B (en) 2014-07-30
JP2014500885A (ja) 2014-01-16
HK1187611A1 (en) 2014-04-11
CN103228631A (zh) 2013-07-31
AU2011336217B2 (en) 2015-10-01
EP2646417A1 (en) 2013-10-09
KR20130098421A (ko) 2013-09-04
US8487104B2 (en) 2013-07-16
IL226668A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
MX2013005915A (es) Inhibidores de kat ii.
MX2011013870A (es) Compuestos biciclicos y triciclicos como inhibidores de quinurenina aminotransferasa ii.
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
EP4257131A3 (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MY165728A (en) Selective glycosidase inhibitors and uses thereof
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
NZ624068A (en) Fused tricyclic compounds as raf kinase inhibitors
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
CL2012001139A1 (es) Compuestos derivados de imidazo[1.2-b]piridazina, inhibidores de pde10; composicion farmaceutica; procedimiento de preparacion; util para el tratamiento o prevencion de un trastorno del snc, tales como trastornos psicoticos, de ansiedad, del movimiento, del humor, neurodegenerativos, metabolicos y del dolor, entre otros.
NZ624063A (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
EA201491083A1 (ru) Фармацевтические композиции 7-(6-(2-гидроксипропан-2-ил)пиридин-3-ил)-1-((транс)-4-метоксициклогексил)-3,4-дигидропиразино[2,3-b]пиразин-2(1н)-она, их твердые формы и способы их применения
MD20150023A2 (ro) Piridinone biciclice noi
CL2011002382A1 (es) Uso de un compuesto derivado de quinazolina-2,4-diona para el tratamiento y/o la prevencion de trastornos asociados al sistema nervioso central y/o al sistema nervioso periferico, preferentemente trastornos asociados a esquizofrenia, enfermedad de parkinson y enfermedad de alzheimer.
NZ630489A (en) Bicyclic pyrazinone derivatives
PH12015500883A1 (en) Heteroaromatic compounds as dopamide d1 ligands
EA201491116A1 (ru) Производные 6-дифторметил-5,6-дигидро-2h-[1,4]оксазин-3-амина
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
GEP201606552B (en) Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
EP2242364A4 (en) PREPARATION AND SANANTIOMERIC SEPARATION OF NONANE OF 7- (3-PYRIDINYL) -1,7-DIAZASPIROÝ4.4 AND NEW FORMS OF SALT OF RACEMATE AND ENANTIOMERS
IN2014DN09826A (es)
WO2012168213A3 (en) Novel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
MX2009011541A (es) Derivados de isoquinolinona como antagonistas nk3.
WO2014057439A3 (en) Compositions and methods for treatment of neurological diseases and its associated complications

Legal Events

Date Code Title Description
FA Abandonment or withdrawal